Rankings
▼
Calendar
URGN Q4 2023 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$927M
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$24M
+30.1% YoY
Gross Profit
$21M
90.3% margin
Operating Income
-$15M
-62.1% margin
Net Income
-$26M
-110.6% margin
EPS (Diluted)
$-0.72
QoQ Revenue Growth
+12.8%
Cash Flow
Operating Cash Flow
-$13M
Free Cash Flow
-$13M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$178M
Total Liabilities
$244M
Stockholders' Equity
-$65M
Cash & Equivalents
$96M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$24M
$18M
+30.1%
Gross Profit
$21M
$16M
+34.2%
Operating Income
-$15M
-$20M
+28.0%
Net Income
-$26M
-$29M
+9.9%
Revenue Segments
Jelmyto
$44M
100%
← FY 2023
All Quarters
Q1 2024 →